TNF-a Signaling Identified as Key Driver in Cancer Development

A team led by Ataman Sendoel from the University of Zurich has found that a distinct TNF-α (tumor necrosis factor alpha) signaling program plays a crucial role in driving clonal expansions in human epithelia and predisposing cells to tumor initiation.

Using an innovative single-cell CRISPR technique, the researchers analyzed 150 cancer genes across entire epithelial tissues with unprecedented precision. They discovered that during clonal expansion in normal epithelia, TNF-α signaling from the surrounding environment, including immune cells, promotes the proliferation of cells with cancer gene mutations.

The study, published in Nature, challenges traditional views of clonal expansions as mere precursors to cancer, revealing a more complex picture. While clonal expansions are common in aging human epithelia and can sometimes prevent tumors, the TNF-α program appears to be a critical factor in determining which cell clones transform into malignant tumors.

Intriguingly, as cancer formation progresses, some cancer cells begin producing their own TNF-α, promoting invasion into surrounding tissue. This self-sustaining mechanism marks a crucial step in tumorigenesis.

The research team's findings have significant implications for cancer detection and treatment. As Sendoel notes, "Our findings indicate that targeting the cancer-specific arm of TNF-α signaling might offer a promising therapeutic avenue for patients with epithelial cancers." Moreover, the activity level of this signaling program correlates with tumor aggressiveness, potentially serving as a biomarker for patient prognosis.